The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases.

atherosclerotic cardiovascular disease chronic kidney disease chronic obstructive pulmonary disease cognitive impairment extrahepatic carcinoma extrahepatic diseases metabolic-associated fatty liver disease multi-organ diseases sarcopenia thyroid disease

Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
23 Feb 2023
Historique:
received: 02 02 2023
revised: 19 02 2023
accepted: 21 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 15 3 2023
Statut: epublish

Résumé

Fatty liver is known to be associated with extra-hepatic diseases including atherosclerotic cardiovascular disease and extra-hepatic cancers, which affect the prognosis and quality of life of the patients. The inter-organ crosstalk is mediated by metabolic abnormalities such as insulin resistance and visceral adiposity. Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed as a new definition for fatty liver. MAFLD is characterized by the inclusion criteria of metabolic abnormality. Therefore, MAFLD is expected to identify patients at high risk of extra-hepatic complications. In this review, we focus on the relationships between MAFLD and multi-organ diseases. We also describe the pathogenic mechanisms of the inter-organ crosstalk.

Identifiants

pubmed: 36904122
pii: nu15051123
doi: 10.3390/nu15051123
pmc: PMC10005526
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP22fk0210090

Références

Aliment Pharmacol Ther. 2020 Apr;51(7):728-736
pubmed: 32043602
Hepatol Res. 2022 May;52(5):422-432
pubmed: 34472683
Metabolism. 2022 Feb;127:154955
pubmed: 34915036
J Clin Transl Hepatol. 2022 Apr 28;10(2):230-237
pubmed: 35528974
Lancet Diabetes Endocrinol. 2018 Dec;6(12):944-953
pubmed: 30389323
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):491-502
pubmed: 29609501
Clin Gastroenterol Hepatol. 2021 Apr;19(4):788-796.e4
pubmed: 32407969
Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8
pubmed: 19049831
Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390
pubmed: 35248211
J Hepatol. 2017 Nov 02;:
pubmed: 29150142
Hepatol Res. 2016 Sep;46(10):951-63
pubmed: 27481650
JHEP Rep. 2021 Jan 19;3(2):100231
pubmed: 33748726
J Hepatol. 2020 Apr;72(4):785-801
pubmed: 32059982
Hepatology. 2021 Nov;74(5):2410-2423
pubmed: 33811766
PLoS One. 2020 Nov 13;15(11):e0241770
pubmed: 33186403
Eur J Epidemiol. 2019 Mar;34(3):259-265
pubmed: 30182324
J Gastroenterol. 2021 Nov;56(11):1022-1032
pubmed: 34601620
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Liver Int. 2022 Feb;42(2):277-287
pubmed: 34953098
J Hepatol. 2017 Dec;67(6):1265-1273
pubmed: 28803953
Biomedicines. 2021 Oct 05;9(10):
pubmed: 34680518
J Hepatol. 2019 Dec;71(6):1229-1236
pubmed: 31470068
Hepatol Commun. 2022 Jan;6(1):120-132
pubmed: 34558835
Hepatology. 2022 Feb;75(2):419-429
pubmed: 34453359
J Endocrinol Invest. 2015 Aug;38(8):817-25
pubmed: 26003827
Gut. 2023 Jan;72(1):141-152
pubmed: 34933916
Hepatol Int. 2020 Dec;14(6):889-919
pubmed: 33006093
Endocr Pract. 2022 Jul;28(7):667-672
pubmed: 35364328
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Trends Endocrinol Metab. 2022 Jun;33(6):424-442
pubmed: 35491295
Hepatology. 2017 Dec;66(6):2055-2065
pubmed: 28777879
J Diabetes Investig. 2023 Mar;14(3):463-478
pubmed: 36566480
Eur J Endocrinol. 2020 Feb;182(2):157-164
pubmed: 31770104
Clin Gastroenterol Hepatol. 2022 Apr;20(4):e855-e875
pubmed: 33387670
Front Endocrinol (Lausanne). 2023 Jan 20;14:1109615
pubmed: 36742393
PLoS One. 2022 May 31;17(5):e0269265
pubmed: 35639744
Nat Rev Nephrol. 2022 Apr;18(4):259-268
pubmed: 35013596
Nutrients. 2022 Nov 04;14(21):
pubmed: 36364937
Clin Mol Hepatol. 2022 Apr;28(2):269-272
pubmed: 35164434
Lancet. 2019 Nov 30;394(10213):2012-2024
pubmed: 31727409
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2953-2960
pubmed: 36222309
Metabolism. 2021 Feb;115:154433
pubmed: 33212070
Clin Mol Hepatol. 2022 Apr;28(2):150-163
pubmed: 34753279
Cardiovasc Diabetol. 2022 Nov 12;21(1):240
pubmed: 36371249
Clin Gastroenterol Hepatol. 2023 Feb;21(2):406-414.e7
pubmed: 35124272
J Clin Transl Hepatol. 2022 Dec 28;10(6):1034-1041
pubmed: 36381086
Nat Rev Endocrinol. 2014 Aug;10(8):455-465
pubmed: 24935119
Int J Mol Sci. 2021 May 22;22(11):
pubmed: 34067258
J Hepatol. 2021 Dec;75(6):1284-1291
pubmed: 34380057
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Metabolites. 2022 Jul 22;12(8):
pubmed: 35893242
Diabetes Metab. 2022 Jul;48(4):101344
pubmed: 35346856
Liver Int. 2020 Jan;40(1):101-106
pubmed: 31472085
Diabetol Metab Syndr. 2022 Aug 16;14(1):115
pubmed: 35974418
Front Endocrinol (Lausanne). 2021 Dec 23;12:782391
pubmed: 35002965
Liver Int. 2020 Dec;40(12):3018-3030
pubmed: 32997882
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10
pubmed: 33348045
Prog Lipid Res. 2018 Jan;69:11-20
pubmed: 29175445
J Hepatol. 2021 Oct;75(4):987-989
pubmed: 34153396
Nephrol Dial Transplant. 2023 Feb 28;38(3):700-711
pubmed: 35612975
Gut. 2022 Apr;71(4):778-788
pubmed: 33685968
Hepatol Int. 2023 Feb;17(1):202-214
pubmed: 36194337
Metabolism. 2022 Nov;136:155294
pubmed: 35995280
Hepatol Res. 2022 Aug;52(8):699-711
pubmed: 35585481
Eat Weight Disord. 2018 Jun;23(3):293-302
pubmed: 29637521
J Clin Endocrinol Metab. 2023 Jan 13;:
pubmed: 36637992
Hepatol Res. 2023 Feb;53(2):104-115
pubmed: 36149726
BMC Gastroenterol. 2023 Jan 5;23(1):3
pubmed: 36604612
Front Endocrinol (Lausanne). 2022 Jun 30;13:891382
pubmed: 35846319
Hepatol Res. 2015 Apr;45(4):363-77
pubmed: 25832328
Gut. 2021 Jul;70(7):1375-1382
pubmed: 33037056
Med Sci Monit. 2022 Sep 12;28:e938365
pubmed: 36093924
Clin Chim Acta. 2023 Jan 1;538:203-210
pubmed: 36549641
Hepatol Res. 2021 Jul;51(7):803-812
pubmed: 33998102
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1168-1178
pubmed: 34337887
Clin Transl Gastroenterol. 2022 Jan 12;13(1):e00435
pubmed: 35080508
Expert Opin Investig Drugs. 2020 Feb;29(2):99-101
pubmed: 31868036
Hepatol Res. 2021 Nov;51(11):1115-1128
pubmed: 34129272
J Diabetes Investig. 2022 Feb;13(2):308-316
pubmed: 34561962
Osteoporos Int. 2023 Jan 31;:
pubmed: 36719471
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1625-1633.e1
pubmed: 30476585

Auteurs

Tsubasa Tsutsumi (T)

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Dan Nakano (D)

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Ryuki Hashida (R)

Department of Orthopedics, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Tomoya Sano (T)

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Machiko Kawaguchi (M)

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Keisuke Amano (K)

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Takumi Kawaguchi (T)

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH